BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,112,603 | +10.6% | 42,192 | -27.8% | 0.00% | 0.0% |
| Q2 2023 | $1,005,685 | +123296.9% | 58,470 | +18.8% | 0.00% | 0.0% |
| Q1 2023 | $815 | +136.2% | 49,202 | +8.6% | 0.00% | +100.0% |
| Q4 2022 | $345 | -99.9% | 45,317 | -10.0% | 0.00% | -33.3% |
| Q3 2022 | $500,000 | -17.5% | 50,363 | -24.7% | 0.00% | 0.0% |
| Q2 2022 | $606,000 | -33.8% | 66,839 | -26.0% | 0.00% | -25.0% |
| Q1 2022 | $915,000 | -95.1% | 90,288 | -91.9% | 0.00% | -95.3% |
| Q4 2021 | $18,500,000 | -52.8% | 1,109,233 | +32.5% | 0.09% | -58.3% |
| Q3 2021 | $39,224,000 | -22.7% | 836,914 | +0.6% | 0.21% | -28.0% |
| Q2 2021 | $50,722,000 | +0.5% | 832,084 | +1.5% | 0.29% | -16.4% |
| Q1 2021 | $50,488,000 | -8.6% | 819,632 | +5.5% | 0.34% | -18.2% |
| Q4 2020 | $55,253,000 | – | 777,031 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |